636 related articles for article (PubMed ID: 33216206)
21. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
22. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
Otani R; Uzuka T; Higuchi F; Matsuda H; Nomura M; Tanaka S; Mukasa A; Ichimura K; Kim P; Ueki K
Cancer Sci; 2018 Jul; 109(7):2327-2335. PubMed ID: 29752851
[TBL] [Abstract][Full Text] [Related]
23. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
24. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
[TBL] [Abstract][Full Text] [Related]
25. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
26. Integrated analysis of mismatch repair system in malignant astrocytomas.
Rodríguez-Hernández I; Garcia JL; Santos-Briz A; Hernández-Laín A; González-Valero JM; Gómez-Moreta JA; Toldos-González O; Cruz JJ; Martin-Vallejo J; González-Sarmiento R
PLoS One; 2013; 8(9):e76401. PubMed ID: 24073290
[TBL] [Abstract][Full Text] [Related]
27. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma.
Richardson TE; Yokoda RT; Rashidipour O; Vij M; Snuderl M; Brem S; Hatanpaa KJ; McBrayer SK; Abdullah KG; Umphlett M; Walker JM; Tsankova NM
Neurooncol Adv; 2023; 5(1):vdad085. PubMed ID: 37554222
[TBL] [Abstract][Full Text] [Related]
29. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
30. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
31. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
[TBL] [Abstract][Full Text] [Related]
32. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
[TBL] [Abstract][Full Text] [Related]
33. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
34. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
[TBL] [Abstract][Full Text] [Related]
35. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.
Hadad S; Gupta R; Oberheim Bush NA; Taylor JW; Villanueva-Meyer JE; Young JS; Wu J; Ravindranathan A; Zhang Y; Warrier G; McCoy L; Shai A; Pekmezci M; Perry A; Bollen AW; Phillips JJ; Braunstein SE; Raleigh DR; Theodosopoulos P; Aghi MK; Chang EF; Hervey-Jumper SL; Costello JF; de Groot J; Butowski NA; Clarke JL; Chang SM; Berger MS; Molinaro AM; Solomon DA
Acta Neuropathol; 2023 Dec; 147(1):3. PubMed ID: 38079020
[TBL] [Abstract][Full Text] [Related]
36. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
37. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
38. Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas.
Bedics G; Szőke P; Bátai B; Nagy T; Papp G; Kránitz N; Rajnai H; Reiniger L; Bödör C; Scheich B
Sci Rep; 2023 Oct; 13(1):18436. PubMed ID: 37891325
[TBL] [Abstract][Full Text] [Related]
39. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.
Wiestler B; Claus R; Hartlieb SA; Schliesser MG; Weiss EK; Hielscher T; Platten M; Dittmann LM; Meisner C; Felsberg J; Happold C; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Grimm C; Weichenhan D; Tews B; Reifenberger G; Capper D; Müller W; Plass C; Weller M; Wick W;
Neuro Oncol; 2013 Aug; 15(8):1017-26. PubMed ID: 23595628
[TBL] [Abstract][Full Text] [Related]
40. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
Tesileanu CMS; Vallentgoed WR; French PJ; van den Bent MJ
Eur J Cancer; 2022 Nov; 175():214-223. PubMed ID: 36152406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]